Abivax’s obefazimod rallied after new clinical data in its Phase 3 ulcerative colitis program reassured investors on benefit and tolerability. The company said ABTECT Maintenance Part 2 showed meaningful clinical benefit, including remission outcomes at Week 44 in induction nonresponders and evidence for dose-escalation recapture in patients who relapsed. Equity reaction followed earlier volatility tied to disclosed malignancy cases in nine patients among 580 enrolled. In the latest disclosure, Abivax reported four non-melanoma skin cancer cases and said malignancy incidence rates, including exposure-adjusted estimates, stayed within pre-defined background ranges used in earlier UC studies. Analysts and investors focused on whether the updated safety framing would offset prior concerns and stabilize the risk perception around longer-duration immunotherapy exposure. Abivax said no new safety signals emerged since the earlier disclosure. The stock move emphasizes how quickly confirmatory datasets and refined safety accounting can influence valuation for late-stage inflammation drug developers.